Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice—Insights From the CANHEART Study

BACKGROUND: The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial decreased major adverse cardiovascular events with very low‐dose rivaroxaban and aspirin in patients with coronary artery disease and peripheral artery disease. We examined the eligibility and potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheth, Maya S., Yu, Bing, Chu, Anna, Porter, Joan, Tam, Derrick Y, Ferreira‐Legere, Laura E., Goodman, Shaun G., Farkouh, Michael E., Ko, Dennis T., Abdel‐Qadir, Husam, Udell, Jacob A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798819/
https://www.ncbi.nlm.nih.gov/pubmed/36515238
http://dx.doi.org/10.1161/JAHA.122.026553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798819/
https://www.ncbi.nlm.nih.gov/pubmed/36515238
http://dx.doi.org/10.1161/JAHA.122.026553

Ejemplares similares